See more : Leo Group Co., Ltd. (002131.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Quince Therapeutics, Inc. (QNCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quince Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Elysee Development Corp. (ASXSF) Income Statement Analysis – Financial Results
- THG Plc (THGHY) Income Statement Analysis – Financial Results
- CLPS Incorporation (CLPS) Income Statement Analysis – Financial Results
- Four Seas Mercantile Holdings Limited (0374.HK) Income Statement Analysis – Financial Results
- Marimekko Oyj (0JX9.L) Income Statement Analysis – Financial Results
Quince Therapeutics, Inc. (QNCX)
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| Gross Profit | -322.00K | -175.00K | -344.00K | -332.00K | -188.00K | -51.00K | -45.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 7.48M | -997.00K | -247.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 3.48M | 1.07M | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 568.00K | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -31.26M | -52.02M | -89.97M | -78.56M | -38.98M | -12.07M | -10.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.04M | 71.00K | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -31.58M | -51.94M | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -197.00K | -284.00K | -620.00K | 2.17M | -188.00K | 357.00K | 1.87M |
| Net Income | -31.39M | -51.66M | -89.33M | -76.85M | -36.79M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| EPS Diluted | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline...
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child...
Quince Therapeutics to Participate at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming...
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Quince's transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel's earlier trial. Chances for success are high, with approval and...
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in The...
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the first patient has been...
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug...
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development...
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief...
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
Two microcap biotech stocks to consider for the science-challenged among us.
Source: https://incomestatements.info
Category: Stock Reports